US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Attovia Therapeutics (ATTO): ATTOBODY Platform Draws Interest with Sector Dedicated Investors

Attovia Therapeutics (ATTO): Healthy Debut as Strong Demand Carries Shares Higher

IPOs and Secondary Offerings

Equity Capital Markets

Attovia Therapeutics / Equity Capital Markets

<ul>
<li>Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.</li>
<li>Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.</li>
<li>Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.</li>
</ul>


Clinical-Stage biotech leveraging the proprietary ATTOBODY platform, with lead candidate ATTO-1310 completing Phase 1 and two additional pipeline programs advancing toward the clinic.
Seeking approximately $182 million to fund clinical development, expand its pipeline, and support operations as it advances multiple immune-mediated disease programs.
Early-Stage, Phase 1 IPO backed by Frazier Life Sciences and licensed from Alamar Biosciences, making institutional demand likely to be the key trading catalyst.


Attovia Therapeutics (ATTO): Phase 1 Immune Therapy Biotech Sets Terms for IPO